Nialamide
Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.[1] It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.[2][3]
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.073 ![]() |
Chemical and physical data | |
Formula | C16H18N4O2 |
Molar mass | 298.346 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
The antiatherogenic activity of nialamide was used to design pyridinolcarbamate.[4]
See also
References
- William Andrew Publishing (1 December 2006). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
- Shayne C. Gad (26 April 2012). Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. pp. 138–. ISBN 978-1-4398-4567-7.
- Edward Shorter (28 September 2008). Before Prozac : The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 137–. ISBN 978-0-19-970933-5.
- Bencze, W. L.; Dempsey, M. E.; Eisenberg, S.; Felts, J. M.; Frantz, I. D.; Hess, R.; Levy, R. I.; Miettinen, T. A.; Rudel, L. L.; Sodhi, H. S.; Stäubli, W.; Zemplényi, T. (6 December 2012). "Hypolipidemic Agents". Springer Science & Business Media. Retrieved 3 October 2017 – via Google Books.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.